Aerosolized Apelin Peptide Formulation for Respiratory Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating coronavirus-associated diseases, such as COVID-19, are inadequate due to the high transmissibility and mutation rate of coronaviruses, limiting the effectiveness of vaccine-based and anti-viral strategies.
Innovation Solution
Administration of an apelin formulation comprising an apelin peptide, either aerosolized, parenteral, or oral, encapsulated in liposomes with components like poloxamer, DSPC, DPPC, and PEG, to enhance innate immune defense and ACE2 activity, providing cardio-pulmonary protection and anti-inflammatory benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccine-based approaches are used to prevent coronavirus infection, then immunity can be built up, but the continual mutation of the virus causes limited success and requires continuous catch-up cycles
Solution Approach 1:
The patent applies preliminary action by administering apelin peptide formulations before coronavirus infection occurs to enhance innate immune defense and ACE2 activity, creating pre-conditioned protective effects that may reduce severity upon exposure without requiring continuous vaccine updates
Solution Approach 2:
The patent uses apelin peptide as an intermediary substance that modulates the host's innate immune system and ACE2 receptor activity, providing a mechanism that is less susceptible to viral mutation compared to direct vaccine approaches
2Reliability
If anti-viral strategies are used to treat coronavirus infection, then viral replication can be inhibited, but continual viral variation causes limited success
Solution Approach 1:
The apelin peptide acts as an intermediary that enhances host cellular defenses and ACE2 activity, creating a protective mechanism that is inherently more resistant to viral variation compared to direct anti-viral drugs that target specific viral proteins
Solution Approach 2:
The formulation leverages the host's own apelin peptide production system to enhance innate immune responses, allowing the body's self-defensive mechanisms to combat the virus rather than relying on external anti-viral agents that may become ineffective due to viral mutation
3Speed
If aerosolized apelin formulation is administered, then rapid delivery to respiratory system can be achieved, but formulation stability and delivery control become more difficult
Solution Approach 1:
The patent modifies the physical and chemical parameters of the apelin peptide formulation to create an aerosolizable composition with appropriate particle size, stability, and delivery characteristics that balance rapid administration with formulation control
Solution Approach 2:
The aerosol delivery system acts as an intermediary mechanism that enables rapid transport of the apelin peptide formulation to the respiratory system while managing the complexity of formulation stability through controlled aerosolization parameters
Data Source
AI summary
The present disclosure provides apelin formulations, and methods and devices of delivering apelin formulations to an individual. Also provided are methods of preventing and/or treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of an apelin formulation comprising an apelin peptide.